RETRACTED: Enalapril/lercanidipine combination on markers of cardiovascular risk: a randomized study

Grundy, 2004, Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines, Circulation, 110, 227, 10.1161/01.CIR.0000133317.49796.0E Derosa, 2012, Evaluation of emerging biomarkers in cardiovascular risk stratification of hypertensive patients: a 2-year study, Curr Med Res Opin, 28, 1435, 10.1185/03007995.2012.717527 Scanu, 1992, Lipoprotein(a). A genetic risk factor for premature coronary heart disease, JAMA, 267, 3326, 10.1001/jama.1992.03480240088040 Bhavani, 2003, Plasma lipoprotein (a) levels in patients with untreated essential hypertension, Indian J Hum Genet, 9, 65 Catalano, 1998, Lp(a) in hypertensive patients, J Hum Hypertens, 12, 83, 10.1038/sj.jhh.1000540 Brett, 1993, Survey of the distribution of a newly characterized receptor for advanced glycation end products in tissues, Am J Pathol, 143, 1699 Malherbe, 1999, cDNA cloning of a novel secreted isoform of the human receptor for advanced glycation end products and characterization of cells co-expressing cell-surface scavenger receptors and Swedish mutant amyloid precursor protein, Brain Res Mol Brain Res, 71, 159, 10.1016/S0169-328X(99)00174-6 Falcone, 2005, Plasma levels of soluble receptor for advanced glycation end products and coronary artery disease in nondiabetic men, Arterioscler Thromb Vasc Biol, 25, 1032, 10.1161/01.ATV.0000160342.20342.00 Koyama, 2005, Plasma level of endogenous secretory RAGE is associated with components of the metabolic syndrome and atherosclerosis, Arterioscler Thromb Vasc Biol, 25, 2587, 10.1161/01.ATV.0000190660.32863.cd Ferroni, 2008, Soluble CD40L and its role in essential hypertension: diagnostic and therapeutic implications, Cardiovasc Hematol Disord Drug Targets, 8, 194, 10.2174/187152908785849125 Abu-Soud, 2000, Nitric oxide is a physiological substrate for mammalian peroxidases, J Biol Chem, 275, 37524, 10.1074/jbc.275.48.37524 Eiserich, 2002, Myeloperoxidase, a leukocyte-derived vascular NO oxidase, Science, 296, 2391, 10.1126/science.1106830 Klose, 1978, Enzymatische Bestimmung des Gesamtcholesterins mit dem [Enzymatic dosage of total cholesterolemia by Greiner Selective Analyzer (GSA II)], J Clin Chem Clin Biochem, 15, 121 Wahlefeld, 1974, Triglycerides determination after enzymatic hydrolysis, 18 Havel, 1955, The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum, J Clin Invest, 34, 1345, 10.1172/JCI103182 Friedewald, 1972, Estimation of the concentration of low density lipoprotein in plasma, without use of the preparative ultracentrifuge, Clin Chem, 18, 499, 10.1093/clinchem/18.6.499 Scanu, 1991, Lipoprotein (a): structure, biology and clinical relevance, Adv Intern Med, 36, 249 Uterman, 1987, Protein composition of lipoprotein (a), J Clin Invest, 80, 458 Graf, 1992, Cloning of TRAP, a ligand for CD40 on human T cells, Eur J Immunol, 22, 3191, 10.1002/eji.1830221226 Morishita, 1987, Molecular cloning and characterization of cDNA for human myeloperoxidase, J Biol Chem, 262, 3844, 10.1016/S0021-9258(18)61433-4 Zhang, 1988 Rifai, 1999, Clinical efficacy of an automated high-sensitivity C-reactive protein assay, Clin Chem, 45, 2136, 10.1093/clinchem/45.12.2136 Winer, 1971 Estacio, 1998, Antihypertensive therapy in type 2 diabetes: implications of the appropriate blood pressure control in diabetes (ABCD) trial, Am J Cardiol, 2, R1 Kasiske, 1995, Effects of antihypertensive therapy on serum lipids, Ann Intern Med, 122, 133, 10.7326/0003-4819-122-2-199501150-00010 Brook, 2000, Mechanism of differential effects of antihypertensive agents on serum lipids, Curr Hypertens Rep, 2, 370, 10.1007/s11906-000-0040-0 Weidmann, 1993, Serum lipoproteins during treatment with antihypertensive drugs, J Cardiovasc Pharmacol, 22, S98, 10.1097/00005344-199312050-00016 Ferrari, 1991, Antihypertensive agents, serum lipoproteins and glucose metabolism, Am J Cardiol, 67, 26B, 10.1016/0002-9149(91)90817-5 Chobanian, 1990, The effects of ACE inhibitors and other antihypertensive drugs on cardiovascular risk factors and atherogenesis, Clin Cardiol, 13, VII43 Keane, 1991, The role of altered lipid metabolism in the progression of renal disease: experimental evidence, Am J Kidney Dis, 17, 38 Bakris, 2002, Impact of an ACE inhibitor and calcium antagonist on microalbuminuria and lipid subfractions in type 2 diabetes: a randomised, multi-centre pilot study, J Hum Hypertens, 16, 185, 10.1038/sj.jhh.1001315